May 24 2013 – Reflux Medicine Boosts Survival in Lung Disease

PHILADELPHIA  —  Survival in idiopathic pulmonary fibrosis (IPF) improved significantly in patients treated with proton pump inhibitors (PPIs), adding to a body of literature supporting PPI benefits in IPF, investigators in a retrospective review concluded.

Patients treated with PPIs had a mean transplant-free survival of 3.4 years compared with 1.4 years in a group of patients who did not receive the drugs. Patients with no history of gastroesophageal reflux (GER) or history of PPI use derived even greater benefit from the antireflux therapy.

Subsequent laboratory studies suggested a mechanism for the benefit, beyond antireflux effects: inhibition of dimethylarginine dimethylaminohydrolase (DDAH), which regulates nitric oxide synthetase in fibroblasts from IPF.

Read the entire article at:

http://www.medpagetoday.com/MeetingCoverage/ATS/39379

For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com

 

This entry was posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized and tagged , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>